Krishnaswamy Yeleswaram, Chief Development Officer at Rapport Therapeutics, Inc. (RAPP), sold 360 shares at $34.90 ($13K) on 2026-04-08, disclosed to the SEC on 2026-04-09.
Scheduled sale ($13k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RAPP | SELL | 2026-04-21 | $809K | — | Filing → |
| RAPP | SELL | 2026-04-14 | $696K | — | Filing → |
| RAPP | SELL | 2026-03-26 | $607K | — | Filing → |